VYNE Therapeutics Q4 2022 Earnings Report $2.77 +0.07 (+2.59%) As of 04:00 PM Eastern Earnings HistoryForecast VYNE Therapeutics EPS ResultsActual EPS-$2.60Consensus EPS -$3.24Beat/MissBeat by +$0.64One Year Ago EPSN/AVYNE Therapeutics Revenue ResultsActual Revenue$0.01 millionExpected Revenue$0.12 millionBeat/MissMissed by -$110.00 thousandYoY Revenue GrowthN/AVYNE Therapeutics Announcement DetailsQuarterQ4 2022Date3/9/2023TimeN/AConference Call ResourcesVYNE Earnings History VYNE Therapeutics Earnings HeadlinesVYNE Therapeutics Updates Corporate Presentation and Pipeline ProgressJanuary 21 at 2:05 AM | americanbankingnews.comVyne therapeutics director Patrick Lepore buys $43,800 in stockJanuary 16, 2025 | msn.comDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. January 21, 2025 | Crypto 101 Media (Ad)VYNE Therapeutics: Strategic Pipeline Advancements and Promising Clinical OutlookJanuary 14, 2025 | markets.businessinsider.comSkye Bioscience (NASDAQ:SKYE) and VYNE Therapeutics (NASDAQ:VYNE) Head to Head ContrastJanuary 12, 2025 | americanbankingnews.comVYNE Therapeutics (VYNE) Gets a Buy from BTIGJanuary 8, 2025 | markets.businessinsider.comSee More VYNE Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like VYNE Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on VYNE Therapeutics and other key companies, straight to your email. Email Address About VYNE TherapeuticsVYNE Therapeutics (NASDAQ:VYNE), a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.View VYNE Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Abbott Laboratories (1/22/2025)Amphenol (1/22/2025)GE Vernova (1/22/2025)ICICI Bank (1/22/2025)Johnson & Johnson (1/22/2025)Kinder Morgan (1/22/2025)Procter & Gamble (1/22/2025)Progressive (1/22/2025)Travelers Companies (1/22/2025)CSX (1/23/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
